Albumine solution and modern concepts of infusion therapy: does the story continue?
https://doi.org/10.21292/2078-5658-2019-16-4-56-64
Abstract
Hypoalbuminemia and hypovolemia are independent risk factors for the development of multiple organ dysfunction, the main cause of death in critically ill patients. The use of a human albumin (HA) solution in complex of the fluid therapy affects both of these risk factors. However, more than 75 years of experience of HA use by the medical community and numerous clinical studies have proved its safety but did not lead to a consensus on the clinical effectiveness of its use. Thus, questions remain, and in which patients the use of HA is most appropriate. The authors of this review attempted to summarize the knowledge accumulated by the medical community on the use of HA in the practice of intensive care.
About the Authors
V. V. Kulabukhov
N.V. Sklifosovsky Research Institute for Emergency Medicine, Moscow Health Department
Russian Federation
Russian Federation
Vladimir V. Kulabukhov - Candidate of Medical Sciences, Associate Professor, Leading Researcher.
Moscow
A. A. Konkin
City Clinical Hospital named after V.P. Demikhov, Moscow Health Department
Russian Federation
Andrey A. Konkin - Anesthesiologist and Emergency Physician of Anesthesiology and Intensive Care Department no. 2
Russian Federation
Andrey A. Konkin - Anesthesiologist and Emergency Physician of Anesthesiology and Intensive Care Department no. 2
M. D. Utev
City Clinical Hospital no. 4, Moscow Health Department
Russian Federation
Maksim D. Utev - Anesthesiologist and Emergency Physician
Russian Federation
Maksim D. Utev - Anesthesiologist and Emergency Physician
References
1. Butrov А.V., Borisov А.Yu., Galenko S.V. Regional infusion therapy in critically ill patients. Trudny Patsient, 2006, vol. 4, no. 10, pp. 19-23. (In Russ.)
2. Goldina O.А., Gorbachevskiy Yu.V. Advantage of modern hydroxyethylated starch agents among other plasma-substituting infusion solutions. Vestnik Sluzhby Krovi Rossii, 1998, no. 3, pp. 41-45. (In Russ.)
3. European Medicine Agency. EMA/35795/2018. January 26, 2018. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2018/01/WC500242423.pdf
4. Kulabukhov V.V. Sistema transporta kisloroda u bolnykh v kriticheskikh sostoyaniyakh (predposylki k prognozirovaniyu iskhoda bolezni). Diss. kand. med. nauk. [Oxygen transportation system in critically ill patients (factors for disease outcome prognosis). Cand. Diss.]. Moscow, 2006, 287 p.
5. Selektivnaya plazmofiltratsiya fraktsionatorami plazmy Evaclio™ u patsientov s sindromom mekhanicheskoy zheltukhi. Prakt. ruk-vo. [Selective plasma filtration by the plasma fractionator of Evaclio™ in the patients with obstructive jaundice. Manual]. V.V. Kulabukhov, eds., Moscow, NPF POKARD Publ., 2016, 27 p.
6. Yakhno T.A. Аgregatnoe sostoyanie i kooperativnye reaktsii komponentov tselnoy krovi v norme i patologii. Diss. dokt. med. nauk. [Aggregate state and cooperative reactions of the whole blood components in health and disease. Doct. Diss.]. N. Novgorod, 2011, 317 p.
7. Berger A. Cochrane Injuries Group Albumin Reviewers why albumin may not work. Brit. Med. J., 1998, vol. 317, no. 7153, pp. 235‒240.
8. Caironi P., Langer T., Gattinoni L. Albumin in critically ill patients: the ideal colloid? Curr. Opin. Crit. Care, 2015, vol. 21, no. 4, pp. 302‒308.
9. Caironi P. et al. Albumin replacement in patients with severe sepsis or septic shock. New Engl. J. Med., 2014, vol. 370, no. 15, pp. 1412‒1421.
10. Cohn E.J. The properties and functions of the plasma proteins, with a consideration of the methods for their separation and purification. Chemic. Reviews, 1941, vol. 28, no. 2, pp. 395‒417.
11. Cook D. et al. Is albumin safe? New Engl. J. Med., 2004, vol. 350, no. 22, pp. 2294‒2296.
12. Cope O., Rhinelander F.W. Symposium on the Management of the Cocoanut Grove Burns at the Massachusetts General Hospital: The Problem of Burn Shock Complicated by Pulmonary Damage. Ann. Surgery, 1943, vol. 117, no. 6, pp. 915.
13. Cosnett J.E. Origins of intravenous fluid therapy. Lancet, 1989, vol. 1, no. 8641, pp. 768‒771.
14. Dellinger R.P. et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intens. Care Med., 2013, vol. 39, no. 2, pp. 165‒228.
15. Ebert R.V., Stead E.A., Gibson J.G. Response of normal subjects to acute blood loss: with special reference to the mechanism of restoration of blood volume. Arch. Intern. Med., 1941, vol. 68, no. 3, pp. 578‒590.
16. Erstad B.L., Gales B.J., Rappaport W.D. The use of albumin in clinical practice. Arch. Internal Med., 1991, vol. 151, no. 5, pp. 901‒911.
17. Farrugia A., Robert P. Plasma protein therapies: current and future perspectives. Best Pract. Research Clin. Haematol., 2006, vol. 19, no. 1, pp. 243‒258.
18. Ferrer R. et al. Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients. Expert Rev. Clin. Pharmacol., 2018, vol. 11, no. 2, pp. 125‒137.
19. Finfer S. et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. New Engl. J. Med., 2004, vol. 350, no. 22, pp. 2247‒2256.
20. Foëx B.A. How the cholera epidemic of 1831 resulted in a new technique for fluid resuscitation. Emerg. Med. J., 2003, vol. 20, no. 4, pp. 316‒318.
21. Goltz F. Über den Tonus der Gefäße und seine Bedeutung für die Blutbewegung. 1864.
22. Heyl J.T., Janeway C.A. The use of human albumin in military medicine. I. The theoretical and experimental basis for its use. US Navy Med. Bulletin, 1942, vol. 40, pp. 785‒791.
23. Holler J.G. et al. Shock in the emergency department; a 12 year population based cohort study. Scand. J. Trauma Resusc. Emerg. Med., 2016, vol. 24, no. 1, pp. 87.
24. Lobo S.M. et al. Early determinants of death due to multiple organ failure after noncardiac surgery in high-risk patients. Anesthesia & Analgesia, 2011, vol. 112, no. 4, pp. 877‒883.
25. MacDonald N., Pearse R.M. Are we close to the ideal intravenous fluid? Brit. J. Anaesth., 2017, vol. 119, pp. i63‒i71.
26. Malbrain M.L.N.G., Van Regenmortel N., Owczuk R. It is time to consider the four D’s of fluid management. Anaesthesiology Intensive Therapy, 2015, vol. 47, pp. 1‒5.
27. Marik P.E., Malbrain M.L.N.G. The SEP-1 quality mandate may be harmful: How to drown a patient with 30 mL per kg fluid! Anaesth. Intens. Therapy, 2014.
28. Matejtschuk P., Dash C.H., Gascoigne E.W. Production of human albumin solution: a continually developing colloid. Brit. J. Anaesth., 2000, vol. 85, no. 6, pp. 887‒895.
29. Moeller C. et al. How safe is gelatin? A systematic review and meta-analysis of gelatin-containing plasma expanders vs crystalloids and albumin. J. Crit. Care, 2016, vol. 35, pp. 75‒83.
30. Myburgh J.A., Mythen M.G. Resuscitation fluids. New Engl. J. Med., 2013, vol. 369, no. 13, pp. 1243‒1251.
31. Newhouser L.R., Lozner E.L. The use of human albumin in military medicine. Part III. The standard Army-Navy package of serum albumin human (concentrated). US Navy Med. Bulletin, 1942, vol. 40, pp. 796,
32. Nicholson J.P., Wolmarans M.R., Park G.R. The role of albumin in critical illness. Brit. J. Anaesth., 2000, vol. 85, no. 4, pp. 599‒610.
33. Offringa M. Excess mortality after human albumin administration in critically ill patients: clinical and pathophysiological evidence suggests albumin is harmful. Brit. Med. J., 1998, vol. 317, no. 7153, pp. 223,
34. Perel P., Roberts I., Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. The Cochrane Library, 2013.
35. Perner A. et al. Expert statement for the management of hypovolemia in sepsis. Intens. Care Med., 2018, pp. 1‒8.
36. Quinlan G.J., et al. Administration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletion. Clin. Sci., 1998, vol. 95, no. 4, pp. 459‒465.
37. Reeves R.B. Temperature-induced changes in blood acid-base status: Donnan rCl and red cell volume. J. Applied Physiol., 1976, vol. 40, no. 5, pp. 762‒767.
38. Reviewers C.I.G.A. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Brit. Med. J., 1998, pp. 235‒240.
39. Rhodes A. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016, Intens. Care Med., 2017, vol. 43, no. 3, pp. 304‒377.
40. Rochwerg B. et al. Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann. Intern. Med., 2014, vol. 161, no. 5, pp. 347‒355.
41. Rosenqvist H., Thorsen H.G.R. Macrodex in the treatment of extensive burns. AMA Archives of Surgery, 1951, vol. 62, no. 4, pp. 524‒531.
42. Shao M., Wang S., Parameswaran P.K. Hypoalbuminemia: a risk factor for acute kidney injury development and progression to chronic kidney disease in critically ill patients. Intern. Urology Nephrol., 2017, vol. 49, no. 2, pp. 295‒302.
43. Sudlow G., Birkett D.J., Wade D.N. Further characterization of specific drug binding sites on human serum albumin. Mol. Pharm., 1976, vol. 12, no. 6, pp. 1052‒1061.
44. Taverna M. et al. Specific antioxidant properties of human serum albumin. Ann. Intens. Care, 2013, vol. 3, no. 1, pp. 4.
45. Tullis J.L. Albumin: 2. Guidelines for clinical use. Jama, 1977, vol. 237, no. 5, pp. 460‒463.
46. Vermeulen L.C. et al. A paradigm for consensus: the University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch. Internal Med., 1995, vol. 155, no. 4, pp. 373‒379.
47. Vincent J.L. et al. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respir. Med., 2014, vol. 2, no. 5, pp. 380‒386.
48. Vincent J.L., De Backer D. Circulatory shock. New Engl. J. Med., 2013, vol. 369, no. 18, pp. 1726‒1734.
49. Wiedermann C.J., Wiedermann W., Joannidis M. Causal relationship between hypoalbuminemia and acute kidney injury. World J. Nephrol., 2017, vol. 6, no. 4, pp. 176,
50. Wilkes M.M., Navickis R.J. Patient survival after human albumin administration: a meta-analysis of randomized, controlled trials. Ann. Intern. Med., 2001, vol. 135, no. 3, pp. 149‒164.
51. Woodruff L.M., Gibson S.T.: The clinical evaluation of human albumin. U. S. Navy Medical Bulletin, 1942, vol. 40, pp. 791,
52. Zhang Z., Hong Y., Liu N. Scientific evidence underlying the recommendations of critical care clinical practice guidelines: a lack of high level evidence. Intens. Care Med., 2018, pp. 1-3.
Review
For citations:
Kulabukhov V.V., Konkin A.A., Utev M.D. Albumine solution and modern concepts of infusion therapy: does the story continue? Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2019;16(4):56-64. (In Russ.) https://doi.org/10.21292/2078-5658-2019-16-4-56-64
Email this article 